drugset / Trial / NCT04828005

Pharmacodynamic Evaluation of Intranasal Nalmefene

NCT04828005

Phase 1 Completed 84 enrolled Opiant Pharmaceuticals Inc
RandomizedCrossoverOpen-labelBasic science

Summary

This study is to determine the pharmacodynamics (the effects of the drug and mechanisms of their action within the body) of Nalmefene when given intranasally (IN; into the nose) compared to intranasal naloxone when given to healthy volunteers under steady state opioid agonism.

Timeline

Start
2021-03-30
Primary completion
2022-03-14
Completion
2022-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 3 mg Intranasal
Comparator Naloxone Small molecule 4 mg Intranasal

Indications

No indication recorded.